1. Signaling Pathways
  2. Immunology/Inflammation
  3. Tim3

Tim3

T-Cell Immunoglobulin and Mucin Containing Protein-3; CD366

Tim3 is an immunoglobulin type protein expressed exclusively on the surface of differentiated Th1 cells. It is a co-inhibitory receptor immune checkpoint protein that regulates macrophage activation, and inhibits Th1-mediated auto- and alloimmune responses, and promotes immunological tolerance.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99044
    Sabatolimab
    Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells.
    Sabatolimab
  • HY-P99827
    Cobolimab
    Inhibitor
    Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC).
    Cobolimab
  • HY-163028
    ML-T7
    99.93%
    ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1. ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research.
    ML-T7
  • HY-155175
    TIM-3-IN-2
    Inhibitor 99.36%
    TIM-3-IN-2 (Compound A-41) is a Tim3 inhibitor (KD: 0.61 μM). TIM-3-IN-2 blocks TIM-3 interactions with PtdSer, CEACAM1, and Gal-9. TIM-3-IN-2 inhibits the immunosuppressive function of TIM-3. TIM-3-IN-2 reverses the TIM-3-mediated blockade of the production of proinflammatory cytokines, and maximizes the T-cell antitumor activity against AML cell lines.
    TIM-3-IN-2
  • HY-144987
    RBN013209
    Inhibitor 98.87%
    RBN013209 is an orally active small molecule inhibitor of CD38 with an IC50 of 0.01 to 0.1 μM for human CD38. RBN013209 prevents the conversion of extracellular NAD+ to ADPR or cADPR in tumor cells and PBMCs. RBN013209 can be used in the study of tumor. In addition, RBN013209 enables CAR-T cells to maintain the naive state and central memory state, and decreases the expression of cell activation markers and exhaustion-related inhibitory receptors.
    RBN013209
  • HY-159884
    MG-T-19
    Inhibitor
    MG-T-19 is an effective TIM-3 inhibitor that can suppress the interaction of TIM-3 with PtdSer, CEACAM1, and Gal-9. MG-T-19 can increase the production of tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) in peripheral blood mononuclear cells (PBMCs) from healthy donors, and enhance the ability of PBMCs to inhibit the proliferation of Kasumi-1 cells (an acute myelogenous leukemia cell line).
    MG-T-19
  • HY-139738
    TIM-3-IN-1
    99.15%
    TIM-3-IN-1 (Compound 38) is a TIM-3 inhibitor that can be used for the research of cancer.
    TIM-3-IN-1
  • HY-P990004
    Anti-Mouse TIM-3 Antibody (B8.2C12)
    Inhibitor
    Anti-Mouse TIM-3 Antibody (B8.2C12) is an anti-mouse TIM-3 antibody inhibitor. Anti-Mouse TIM-3 Antibody (B8.2C12) is a rat IgG1κ subtype antibody.
    Anti-Mouse TIM-3 Antibody (B8.2C12)
Cat. No. Product Name / Synonyms Application Reactivity